Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

DrStockPick Provides Updates On FBC, PWRM, AIB and ABK.

drstock-2-3

signup3m


power3

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

************************************************

Ambac Financial Group, Inc. (NYSE:ABK) announced on November 8, 2010 that it has filed for a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York. The Company will continue to operate in the ordinary course of business as “debtor-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The Company was unable to raise additional capital as an alternative to seeking bankruptcy protection and was also unable to agree to terms with an ad-hoc committee of certain senior debt holders in order to restructure its outstanding debt through a prepackaged bankruptcy proceeding. However, Ambac has agreed to a non-binding term sheet that will serve as a basis for further negotiations with the ad-hoc committee and that may allow the Company to emerge from bankruptcy more expeditiously.

Ambac Financial Group, Inc. does not have significant operations. Previously, the company provided financial guarantee insurance and other credit enhancement products in the U.S. public finance market, the U.S. structured finance and asset-backed market, and the international finance market; and financial and investment products, including investment agreements, funding conduits, interest rate, and currency and total return swaps.

************************************************

Allied Irish Banks plc (NYSE:AIB) announced that it has transferred loans for a further 20 customers to NAMA totalling EUR3.2bn. As previously stated, NAMA has estimated the overall discount to be applied to the remaining c.EUR13.5bn of loans to transfer to NAMA, by year end, including these loans, at 60%. AIB has agreed with NAMA that the final tranche can complete on a phased basis. This transfer is part of the final tranche of EUR13.5bn of loans that are intended to transfer to NAMA.

Allied Irish Banks, p.l.c., together with its subsidiaries, provides retail and corporate banking, investment banking, and asset management services in the Republic of Ireland and internationally. The company accepts demand deposits, time deposits, and current accounts, as well as provides lending services, such as vehicle, plant, machinery, and equipment leasing; retail and investment property loans; vehicle, plant, machinery, and equipment hire purchase; and personal loans.

************************************************

Flagstar Bancorp Inc. (NYSE:FBC) announced that it will present on Thursday, November 11, 2010 at the Sandler O’Neill 2010 East Coast Financial Services Conference, which is taking place in Aventura, Florida. Attending the conference for Flagstar Bancorp will be Joseph P. Campanelli, Chairman and Chief Executive Officer, and Paul Borja, Chief Financial Officer. Flagstar is scheduled to speak at the conference beginning at approximately 4:05 p.m. Eastern. Attendance at the conference is by invitation only, however a live audio webcast and an accompanying slide presentation will be publicly available on Flagstar’s website under the Investor Relations section at the time of the presentation.

Flagstar Bancorp, Inc. operates as the holding company for Flagstar Bank, FSB that offers consumer and commercial financial products and services to individuals, and small and middle market businesses in Michigan, Indiana, and Georgia. The company engages in generating deposits and originating loans.

******************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).